News

Year: 
2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001
12/5/2008 Crise traz oportunidades para fundos de mercado secundario
12/3/2008 Secondary Firm Paul Capital Boosts London Team to Handle Deal Flow
12/1/2008 Revenue Interest Financing: A Strategic Alternative to Accessing Capital through Licensing in the Life Sciences
11/24/2008 Hard Times for Private Equity
11/10/2008 Illiquid Assets: A Buyer’s Perspective
10/2/2008 Celldex Receives $10 Million Milestone Payment
9/30/2008 PLETHORA SOLUTIONS HOLDINGS PLC Clinical Update - PSD502 for Premature Ejaculation Completion of European Phase III Trial
9/30/2008 A.P. Pharma Announces Positive Phase 3 Results with APF530 in the Prevention of CINV Company on Track to Submit NDA in the Fourth Quarter of 2008 Conference Call Begins Today at 9:00 A.M. Eastern Time
9/30/2008 Lehman to Spin off Venture Capital Arm?
9/29/2008 David de Weese of Paul Capital Partners on the Economic Turmoil’s Effect on the Secondary Market
9/29/2008 AVANT Immunotherapeutics Announces Name Change to Celldex Therapeutics - Anthony S. Marucci Appointed President and CEO - - Celldex to Trade Under NASDAQ Symbol CLDX Effective October 1
9/26/2008 Pharming's Board Of Supervisory Directors Nominates New CEO / Dr Pinto to retire after completion of transition period
9/25/2008 Glenmark dermatology line expands with recent U.S. FDA approval
9/24/2008 Dyax Announces Completion of Biologics License Application for DX-88 for Hereditary Angioedema
9/16/2008 Orthovita Files Response to FDA's Initial Review of the CORTOSS 510(k) Application
9/11/2008 Glenmark to initiate Phase I studies for GBR 500 by filing its IND application with the US-FDA
9/8/2008 SpePharm has selected Alloga as its European logistic partners
8/21/2008 TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare enter into ?26 Million Financing of SpePharm
8/21/2008 TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare enter into €26 Million Financing of SpePharm
8/20/2008 JHP Pharmaceuticals and SpePharm complete purchase of Dantrium®
7/24/2008 Paul Capital Partners Promotes Ken Macleod to Partner
7/11/2008 Pharming Announces Positive Results From Rhucin® Open-label Clinicial Studies
6/19/2008 Clinical Update – PSD502 for Premature Ejaculation Completion of Recruitment for European Phase III Trial
6/16/2008 Pharming Announces Positive Results From North American Randomized Trial With Rhucin®
6/9/2008 Paul Capital Healthcare Leads Panel on Strategic Financing
5/30/2008 Glenmark Generics receives three ANDA approvals
5/5/2008 Paul Capital Closes $1.65 Billion Secondaries Fund
4/21/2008 Vernalis and Paul Capital Healthcare Sign €18.4 Million Financing Agreement
4/10/2008 Glenmark completes preclinical development for initiating Phase I trials for GBR 500 – a monoclonal antibody for Inflammation
4/8/2008 Paul Capital Looks to Build Asia Secondary Niche
4/4/2008 FDA Approves ROTARIX® Rotavirus Vaccine
4/1/2008 Plethora and Paul Capital Healthcare Sign a $25 Million Revenue Interest Financing Agreement
3/25/2008 Pharming Signs Distribution Agreement For Rhucin® In Turkey
3/20/2008 Pharming To Receive Negative Opinion On European Marketing Authorization Application For Rhucin®
3/17/2008 Glenmark launches Clobetasol from its niche dermatology pipeline
3/7/2008 AVANT Announces Completed Merger with Celldex and 1-for-12 Reverse Stock Split
3/4/2008 Orthovita Announces New VITOSS® Bioactive Foam Bone Graft Substitute
2/28/2008 Dyax Corp. Announces First Market Approval from Licensing and Funded Research Program
2/21/2008 Rotarix® Receives Favorable Recommendation from FDA Advisory Committee
2/6/2008 Glenmark receives USD 15 million as milestone payments from Forest for Oglemilast, GRC 3886
2/4/2008 Acorda Therapeutics Announces Acquisition of Aminopyridine and Pre-Clinical Assets from Neurorecovery, Inc.
1/23/2008 Paul Capital Healthcare Purchases Additional Royalty Interest in Glaxosmithkline's Rotarix®

© 2010 by Paul Capital. All rights reserved.